Elevation Oncology (Elevation Oncology) 6-1 Month Momentum % : 1110.53% (As of May. 11, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Elevation Oncology 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-05-11), Elevation Oncology's 6-1 Month Momentum % is 1110.53%.

The industry rank for Elevation Oncology's 6-1 Month Momentum % or its related term are showing as below:

ELEV's 6-1 Month Momentum % is ranked better than
99.87% of 1531 companies
in the Biotechnology industry
Industry Median: 2.29 vs ELEV: 1110.53

Competitive Comparison of Elevation Oncology's 6-1 Month Momentum %

For the Biotechnology subindustry, Elevation Oncology's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elevation Oncology's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Elevation Oncology's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Elevation Oncology's 6-1 Month Momentum % falls into.

Elevation Oncology (NAS:ELEV) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elevation Oncology (NAS:ELEV) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Elevation Oncology 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Elevation Oncology's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Elevation Oncology (Elevation Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elevation Oncology Inc (NAS:ELEV) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106

Website

https://www.elevationoncology.com

Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.

Executives

Tammy Furlong	officer: CHIEF FINANCIAL OFFICER	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund Iii, L.p.	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Goodman Corey S	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Robert J Adelman	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Aaron Royston	10 percent owner	200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063
David Dornan	officer: Chief Scientific Officer	C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Valerie Malyvanh Jansen	officer: Chief Medical Officer	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Cormorant Asset Management, Lp	10 percent owner	200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116
Andrew N Schiff	other: Managing Member	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Steve Elms	director, other: Managing Member	888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106
Venbio Global Strategic Gp Iii, Ltd	10 percent owner	1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Vertex Global Hc Fund Ii Pte. Ltd.	10 percent owner	250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101
Walsh Colin	director	C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106